Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of house dust mite allergoid immunotherapy in controlled allergic asthma with rhinoconjunctivitis
2011-002248-29Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Dec 2011
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Acaroid in allergic asthma, allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), house dust mite allergy, sponsored by Allergopharma. Started Dec 2011; status: completed.
02
Drugs
Acaroid
03
Conditions
allergic asthmaallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2011-002248-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002248-29.